^
Association details:
| Biomarker: | BCR-ABL1 A397P |
|---|---|
| Cancer: | Chronic Myeloid Leukemia |
| Drug: | imatinib (Bcr-abl inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase
Excerpt:
Mutations were identified in 60 (60%) of these patients (all with imatinib-resistant CML-AP). Among the 60 patients with mutations, 26 unique imatinib-resistant mutations were identified, of which G250E was the most common (n = 9) (Table 5).
DOI:
10.1182/blood-2006-09-046839